Relationship Between Topiramate Use and Ocular Angle Status
Phase 4
- Conditions
- Glaucoma, Angle-Closure
- Registration Number
- NCT00153699
- Lead Sponsor
- Chinese University of Hong Kong
- Brief Summary
We test the hypothesis whether topiramate narrows the angles which may render Asians more likely to suffer from acute angle closure glaucoma.
- Detailed Description
Topiramate is approved for the treatment of epilepsy and prophylaxis of migraine attacks. There were case reports of acute angle closure glaucoma (AACG) associated with its use. AACG is particularly common in Asians because of a higher prevalence of narrow angle., we test the hypothesis whether topiramate narrows the angles which may render them more likely to suffer from AACG.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
- Participants aged 18-75 with an indication for starting topiramate.
Read More
Exclusion Criteria
- Patients with known allergy or intolerance to topiramate.
- Recent exposure to topiramate (<3 months).
- Moderate to severe renal failure.
- Known history of renal calculi or hepatic failure
- Inability to give informed consent.
- Pregnant women or women of child-bearing age who do not practise an acceptable means of contraception.
- Patients known to have angle-closure glaucoma.
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Change(s) in ophthalmic parameters measured at baseline and after 4 weeks of treatment, including: 4 weeks best-corrected visual acuity, refraction, Goldmann applanation tonometry, Gonioscopy, dilated fundus examination, 4 weeks and ultrasound biomicroscopy of angle and anterior segment. 4 weeks
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
Hong Kong Eye Hospital
ðŸ‡ðŸ‡°Kowloon, Hong Kong
Prince of Wales Hospital
ðŸ‡ðŸ‡°Shatin, Hong Kong